metastatic colorectal cancer
Conditions
Interventions
TS-1+ Oxaliplatin+ Bevacizumab/TS-1+ Bevacizumab
Sponsors
Sapporo Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age :<=20 years 2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. 3. Histological confirmation of colorectal cancer. 4. No prior chemotherapy except adjuvant chemotherapy if completed more than 6months prior to enrollment. 5. Measurable or evaluable disease. (RECIST 1.1) 6. survival more than 3 months. 7. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. 8. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Need to drain malignant fluid. 2. With a history of allergic response to Fluorouracil or Levofolinate calcium or Platinium. 3. Pregnant or lactating women or women of childbearing potential. 4. Uncontrolled infection. 5. Evidence of interstinal lung disease, or pulmonary fibrosis. 6. Clinically significant (i.e. active) cardiovascular disease or past or current history (within the last 1 year) of myocardial infarction. 7. Uncontrollable ulcer indigestive tract. 8. Radiological evidence of CNS metastases or brain cancer. 9. Complication of cerebrovascular disease or symptoms within 1 year. 10. Any surgical treatments within 4 weeks. 11. Administering antithrombotic drug within 10 days. Need to administrate or having anti-platelets therapy 12. Multiple primary cancers within 5 years. 13. Other conditions not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DDC ; Duration of disease control | — |
Countries
Japan
Contacts
Public ContactYasushi Sato
Sapporo Medical University School of Medicine Department of Medical Oncology and Hematology
Outcome results
None listed